Thursday 25 April 2019 ,
Thursday 25 April 2019 ,
Latest News
  • Stay alert against terror activities: PM
  • Sri Lanka blasts: Zayan’s body arrives in Dhaka
  • Unspeakable grief: 5 members of 1 family killed in Sri Lanka
  • Death for 2 Netrakona war criminals
  • Death toll rises to 359 in Sri Lanka bombings, more arrested
  • 2 ‘drug traders’ killed in Cox’s Bazar, Dhaka ‘gunfights’
  • Sri Lanka attacker studied in UK, says minister, amid warning more bombers on loose
16 April, 2019 00:00 00 AM

FDA approves Dovato (dolutegravir/lamivudine) for HIV-1 infection

drugs.com
FDA approves Dovato (dolutegravir/lamivudine) for HIV-1 infection

ViiV Healthcare recently announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either DTG or 3TC. Dovato, a two-drug regimen (2DR), reduces exposure to the number of ARVs from the start of treatment, while still maintaining the efficacy and high barrier to resistance of a traditional DTG-based three-drug regimen.

Deborah Waterhouse, CEO, ViiV Healthcare, said: “Building on our innovative portfolio of medicines, Dovato is powered by dolutegravir, an antiretroviral included in multiple combination therapies and the most prescribed integrase inhibitor in the world, 2 coupled with the established profile of lamivudine. With Dovato, the first complete, single-tablet, two-drug regimen for treatment-naïve adults, ViiV Healthcare is delivering what patients are requesting—a chance to treat their HIV-1 infection with as few drugs as possible, marking a significant step in HIV treatment.”

The approval of Dovato is supported by the landmark global GEMINI 1 and 2 studies that included more than 1,400 HIV-1 infected adults. In these studies, DTG + 3TC demonstrated non-inferiority based on plasma HIV-1 RNA <50 copies per milliliter (c/mL), a standard measure of HIV-1 control, at Week 48 when compared to a three-drug regimen of DTG and two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC), in treatment-naïve, HIV-1 infected adults. The safety results for DTG + 3TC seen in GEMINI 1 and 2 were consistent with the product labelling for DTG and 3TC. No patient who experienced virologic failure in either treatment arm developed treatment-emergent resistance.

Pedro Cahn, principal investigator for the GEMINI study program said: “People are now living longer with HIV and will spend a lifetime taking drugs to suppress their virus. The approval of the fixed dose combination of dolutegravir and lamivudine, a complete, single-tablet, two-drug regimen, marks a pivotal moment in the treatment of HIV-1.

Treatment-naïve people living with the virus have a powerful option that delivers non-inferior efficacy to a dolutegravir-based three-drug regimen, allowing them to take fewer ARVs and get and remain suppressed.”

Jeff Berry, Test Positive Aware Network (TPAN), said: “The approval of Dovato is a welcome paradigm shift, as it brings an innovative treatment approach to newly diagnosed adults with HIV-1. By exposing patients to fewer drugs at the start of treatment, the hope is to help address concerns arising from overall management of prolonged ARV therapy.”

About Dovato (dolutegravir/ lamivudine)

Dovato is approved as a complete regimen for the treatment of HIV-1 infection in adults with no known antiretroviral treatment history and with no known substitutions associated with resistance to either dolutegravir or lamivudine.

Dovato is a once-daily, single-tablet, two-drug regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay, 50 mg) with the nucleoside analogue reverse transcriptase inhibitor (NRTI) lamivudine (Epivir, 300 mg).

Like a DTG-based three-drug regimen, Dovato uses only two drugs to inhibit the viral cycle at two different sites. INSTIs, like dolutegravir, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection. Lamivudine is an NRTI that works by interfering with the conversion of viral RNA into DNA which in turn stops the virus from multiplying.

GEMINI 1 and 2 study design

GEMINI 1 (204861) and GEMINI 2 (205543) are duplicate, Phase III, randomized, double-blind, multicenter, parallel group, non-inferiority studies. These studies evaluate a two-drug regimen of dolutegravir and lamivudine compared with a three-drug, first-line regimen of DTG + TDF/FTC in HIV-1 infected, antiretroviral therapy (ART)-naïve adult participants with baseline HIV-1 viral loads up to 500,000 copies per milliliter. The trials are designed to study the efficacy and safety of once-daily dolutegravir and lamivudine compared to once-daily dolutegravir and the fixed-dose combination of TDF/FTC at 48 weeks in HIV-1-infected, ART-naïve adult participants.

Important safety information

The following ISI is based on the Highlights section of the Prescribing Information for Dovato. Please consult the full Prescribing Information for all the labeled safety information for Dovato.

Warning: patients co-infected with hepatitis b virus (hbv) and human immunodeficiency virus (hiv-1): emergence of lamivudine-resistant hbv and exacerbations of  HBV

All patients with HIV-1 should be tested for the presence of HBV prior to or when initiating Dovato. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported.

If Dovato is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.

Severe acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of Dovato. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment

Contraindications

Prior hypersensitivity reaction to dolutegravir or lamivudine.

Coadministration with dofetilide.

Warnings and precautions

Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported with dolutegravir. Discontinue Dovato immediately if signs or symptoms of hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction.

Hepatotoxicity has been reported in patients receiving a dolutegravir-containing regimen. Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with Dovato. Monitoring for hepatotoxicity is recommended.

Embryo-fetal toxicity may occur when used at the time of conception and in early pregnancy. Avoid use of Dovato at the time of conception through the first trimester of pregnancy due to the risk of neural tube defects. Advise individuals of childbearing potential to use effective contraception.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues.

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy.

Adverse reactions

The most common adverse reactions (all grades) observed in ≥2% (in those receiving Dovato) were headache, diarrhea, nausea, insomnia, and fatigue.

Drug interactions

Dovato is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral drugs for the treatment of HIV-1 infection is not recommended.

Refer to the full prescribing information for important drug interactions with Dovato.

Use in specific populations

Pregnancy: Avoid use of Dovato at the time of conception through the first trimester due to the risk of neural tube defects.

Lactation: Breastfeeding is not recommended due to the potential for HIV-1 transmission.

Females and males of reproductive potential: Pregnancy testing and contraception are recommended in individuals of childbearing potential.

Renal Impairment: Dovato is not recommended in patients with creatinine clearance less than 50 mL/min.

Hepatic Impairment: Dovato is not recommended in patients with severe hepatic impairment (Child-Pugh Score C).

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Parkinson’s disease is a slowly progressing, degenerative disorder of the nervous system; Parkinson’s disease has several distinguishing characteristics:…
Cancer professionals need to be aware quality of life is an abstract concept for many patients

Cancer professionals need to be aware quality of life is an abstract concept for many patients

It has been a long consult. Gently adjusting his father’s hearing aid, the attentive son asks: “Dad, you hear what the doctor is saying? The…
Parkinson's disease symptoms, causes, stages, treatment, and life expectancy

Parkinson's disease symptoms, causes, stages, treatment, and life expectancy

SIETSKE N. HEYN, PHD   CHARLES PATRICK DAVIS, MD, PHD   Parkinson's disease is the second most common neurodegenerative disorder and the…
10 Early warning signs of Parkinson's disease

10 Early warning signs of Parkinson's disease

How to tell if you or someone you love might have Parkinson's It can be hard to tell if you have Parkinson's disease. Here are the 10 signs you…
Parkinson’s: Can how you sleep determine if you’ll develop it?

Parkinson’s: Can how you sleep determine if you’ll develop it?

During a symposium held at NNI, Professor Eduardo Tolosa, a neurologist and world-renowned expert on Parkinson Disease (PD) from the University of Barcelona,…
Precise decoding of breast cancer cells creates new option for treatment

Precise decoding of breast cancer cells creates new option for treatment

Researchers at the University of Zurich and from IBM Research have investigated the varying composition of cancer and immune cells in over 100 breast…
Gastroenteritis (Stomach flu) in children: What should parents do

Gastroenteritis (Stomach flu) in children: What should parents do

Gastroenteritis (commonly known as stomach flu) causes discomfort due to the ensuing vomiting and diarrhoea, which are often accompanied by tummy pains…
Sleep myths 'damaging your health'

Sleep myths 'damaging your health'

JAMES GALLAGHER A team at New York University trawled the internet to find the most common claims about a good night's kip. Then, in a study published…
More TV, tablets: Attention issues at age 5

More TV, tablets: Attention issues at age 5

Five-year-olds who spend more than two hours a day in front of a smartphone or tablet may be at risk of attention problems, a new study suggests. Excessive…
15 Remedies for back pain relief

15 Remedies for back pain relief

CATHY WONG Back pain is a health concern for most people in the United States at some point in their lives and one of the most common reasons people miss…
Declaration on the occasion of world health day, april 7, 2019

Declaration on the occasion of world health day, april 7, 2019

On the occasion of World Health Day on 7 April 2019, PHM West Africa & Center (PHM WCA) denounces the rise of fundamentalism and violence in several…
Seminar on ‘Universal Health Coverage to Combat Non-Communicable Diseases’ held

Seminar on ‘Universal Health Coverage to Combat Non-Communicable Diseases’ held

North South University has organized a seminar on ‘Universal Health Coverage to Combat Non-Communicable Diseases’ to observe World Health…
Research, training stressed for flourishing homeopathy

Research, training stressed for flourishing homeopathy

Stressing on conducting research & training on homeopathy in the country, health experts at a seminar said that research can flourish  …
Statins failing to adequately reduce cholesterol in around half of patients

Statins failing to adequately reduce cholesterol in around half of patients

MARIE CLAIRE DORKING Statins are not effective for around half of people taking them, new research has revealed. The cholesterol-lowering drugs taken…
FDA approves Evenity (romosozumab-aqqg)

FDA approves Evenity (romosozumab-aqqg)

The U.S. Food and Drug Administration recently approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting